Comparative Pharmacology
Head-to-head clinical analysis: AZOLID versus LODINE XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZOLID versus LODINE XL.
AZOLID vs LODINE XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically interfering with peptidoglycan cross-linking.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
2 g intravenously every 6-8 hours; maximum 8 g/day.
400 mg or 600 mg orally once daily.
None Documented
None Documented
Terminal half-life 1.5-2 hours in normal renal function; prolonged to 4-8 hours in severe renal impairment (CrCl <30 mL/min)
Clinical Note
moderateFurazolidone + Torasemide
"Furazolidone may increase the hypotensive activities of Torasemide."
Clinical Note
moderateFurazolidone + Travoprost
"Furazolidone may increase the hypotensive activities of Travoprost."
Clinical Note
moderateFurazolidone + Unoprostone
"Furazolidone may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateFurazolidone + Hydrochlorothiazide
"Furazolidone may increase the hypotensive activities of Hydrochlorothiazide."
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
Renal (80-90% unchanged), biliary/fecal (10-20%)
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Category C
Category C
NSAID
NSAID